David Davidson

David joined Tessera in 2021 as Chief Medical and Development Officer. David has over 20 years of expertise in clinical drug development focused on rare diseases and gene therapy.

Most recently, David served as Chief Medical Officer of bluebird bio for nearly a decade, where he played a critical role in advancing a broad genetic medicine pipeline across blood disorders, rare diseases and oncology, successfully leading numerous genetic medicine programs into the clinic and delivering two first-in-class approvals for genetic medicines in the U.S. and Europe. Prior to bluebird bio, David led clinical research for a wide range of therapeutic programs at Genzyme and GelTex, spanning biologics, polymers, and gene therapy.

David completed a fellowship in infectious diseases at the Harvard Longwood Combined ID Program, his residency training in internal medicine and an endocrinology research fellowship at the University of Chicago Hospitals, and received his M.D. from New York University and B.A. from Columbia University.